NASDAQ:ALBOAlbireo Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Albireo Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $25.77 -0.64 (-2.42 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$25.22Now: $25.77▼$26.2050-Day Range$17.43MA: $23.45▼$27.4352-Week Range$11.26Now: $25.77▼$35.76Volume47,700 shsAverage Volume101,114 shsMarket Capitalization$386.03 millionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAlbireo Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.75, Albireo Pharma has a potential upside of 104.7% from its current price of $25.77.Amount of Analyst CoverageAlbireo Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAlbireo Pharma has received 261 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlbireo Pharma has received 280 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlbireo Pharma has received 51.76% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote “Outperform” if you believe ALBO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlbireo Pharma does not currently pay a dividend.Dividend GrowthAlbireo Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Albireo Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,641.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Albireo Pharma is held by insiders.Percentage Held by Institutions69.69% of the stock of Albireo Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Albireo Pharma are expected to grow in the coming year, from ($7.13) to ($5.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Albireo Pharma is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Albireo Pharma is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlbireo Pharma has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALBO Previous Symbol CUSIPN/A CIK1322505 Webwww.albireopharma.com Phone857-254-5555Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.64 million Price / Sales40.05 Cash FlowN/A Price / Cash FlowN/A Book Value$7.34 per share Price / Book3.51Profitability EPS (Most Recent Fiscal Year)($5.04) Net Income$-62,720,000.00 Net Margins-730.55% Return on Equity-72.82% Return on Assets-44.27%Miscellaneous Employees39 Outstanding Shares14,980,000Market Cap$386.03 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ALBO Rates by TradingView Receive ALBO News and Ratings via Email Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions How has Albireo Pharma's stock been impacted by COVID-19 (Coronavirus)? Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALBO shares have increased by 46.2% and is now trading at $25.77. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Albireo Pharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Albireo Pharma. When is Albireo Pharma's next earnings date? Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Albireo Pharma. How were Albireo Pharma's earnings last quarter? Albireo Pharma Inc (NASDAQ:ALBO) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($2.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.39) by $0.84. The biopharmaceutical company earned $1.55 million during the quarter, compared to the consensus estimate of $1.19 million. Albireo Pharma had a negative return on equity of 72.82% and a negative net margin of 730.55%. View Albireo Pharma's earnings history. What price target have analysts set for ALBO? 5 Wall Street analysts have issued 1-year price objectives for Albireo Pharma's stock. Their forecasts range from $39.00 to $62.00. On average, they expect Albireo Pharma's stock price to reach $52.75 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price. View analysts' price targets for Albireo Pharma. Has Albireo Pharma been receiving favorable news coverage? News headlines about ALBO stock have been trending positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Albireo Pharma earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAlbireo Pharma. Who are some of Albireo Pharma's key competitors? Some companies that are related to Albireo Pharma include Akebia Therapeutics (AKBA), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Akcea Therapeutics (AKCA), I-Mab (IMAB), CytoDyn (CYDY), ZEALAND PHARMA/S (ZEAL), Arcus Biosciences (RCUS), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA), Intra-Cellular Therapies (ITCI), Arvinas (ARVN) and Karyopharm Therapeutics (KPTI). View all competitors. What other stocks do shareholders of Albireo Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), Exelixis (EXEL), Palatin Technologies (PTN), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Viking Therapeutics (VKTX), Arcturus Therapeutics (ARCT), Alibaba Group (BABA) and Cornerstone Total Return Fund (CRF). Who are Albireo Pharma's key executives? Albireo Pharma's management team includes the following people: Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 56)Ms. Martha J. Carter, Chief Regulatory Officer (Age 67)Dr. Paresh N. Soni, Consultant (Age 59)Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.Mr. Simon Harford, CFO & Treasurer What is Albireo Pharma's stock symbol? Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO." Who are Albireo Pharma's major shareholders? Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (13.09%), Federated Hermes Inc. (12.77%), ArrowMark Colorado Holdings LLC (6.49%), BlackRock Inc. (5.13%), Chicago Capital LLC (3.30%) and Prosight Management LP (2.21%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View institutional ownership trends for Albireo Pharma. Which major investors are selling Albireo Pharma stock? ALBO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Two Sigma Investments LP, Wells Fargo & Company MN, Victory Capital Management Inc., Victory Capital Management Inc., Parametric Portfolio Associates LLC, and MAI Capital Management. Company insiders that have sold Albireo Pharma company stock in the last year include Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford. View insider buying and selling activity for Albireo Pharma. Which major investors are buying Albireo Pharma stock? ALBO stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Chicago Capital LLC, Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, Prosight Management LP, BlackRock Inc., Deutsche Bank AG, and Geode Capital Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc, and Ronald Harold Wilfred Cooper. View insider buying and selling activity for Albireo Pharma. How do I buy shares of Albireo Pharma? Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Albireo Pharma's stock price today? One share of ALBO stock can currently be purchased for approximately $25.77. How big of a company is Albireo Pharma? Albireo Pharma has a market capitalization of $386.03 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe. What is Albireo Pharma's official website? The official website for Albireo Pharma is www.albireopharma.com. How can I contact Albireo Pharma? Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
